<< MLNM retained all commercial rights for Velcade in the US (which represents 60-70% of the global potential).>>
This is very wrong. Today US economic is ~40-50% of worldwide, but it may (and will) change dramatically in coming years. Global market has significant potential, imo.
That is something I have often wondered about. What are the relations between the US, European and Japanese pharmaceutical markets size-wise?
It seems to be something like this.
North America (USA and Canada): 50,9 %
Europe: 25,4 %
Japan: 11,7 %
Africa, Asia (excl.Japan) and Australia: 7,9 %
Latin America: 4,1 %
Source: EFPIA - European Federation of Pharmaceutical Industries and Associations.
efpia.org
Some other interesting statistics from the same publication.
Total spending on healthcare as a percentage of GDP at market prices for year 2000.
USA: 13 %
Europe: 8,1 %
Japan: 7,8 %
The highest European figure is Switzerland's at 10,7 % and the lowest is Turkey with 4,8 %. Most of the other are found somewhere between 7,5 % and 8,5 %. Considering the budgetary pressures most European countries are facing, I cannot see much room for further expansion of the figure for total health-related costs. Re-distributions between different types of costs are a possibility.
Erik |
